News >

Expert Explains Successes, Challenges in Stage III Lung Cancer

Caroline Seymour
Published: Monday, Aug 27, 2018

Dustin M. Walters, MD

Dustin M. Walters, MD

The heterogeneity of stage III NSCLC means there is not a one-size-fits-all strategy for patients. Rather, a multidisciplinary approach is required to optimally utilize the available tools of chemoradiation, immunotherapy, and surgery.

“We’ll have to figure out how to leverage all the benefits of all those therapies and time them appropriately [versus] a magic bullet or monotherapy that works well for these [patients],” said Dustin M. Walters, MD.

Exciting new data continue to expand the treatment options available for these multidisciplinary strategies. For example, following the readout of the PACIFIC trial, the use of durvalumab (Imfinzi) after chemoradiotherapy became a standard option in the treatment paradigm for patients with unresectable stage III NSCLC. Results of the study demonstrated an 11.2-month improvement in progression-free survival (PFS) with durvalumab versus placebo (16.8 vs 5.6; HR, 0.52; 95% CI, 0.42-0.65; P <.0001). The 18-month PFS rate was 44.2% compared with 27.0% in favor of the durvalumab arm.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication